SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.29

Change

0.00 (-0.34)%

Market Cap

N/A

Volume

753.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-5.16 (-7.22%)

USD 221.48B
AMGN Amgen Inc

+2.38 (+0.75%)

USD 171.55B
SNY Sanofi ADR

-0.10 (-0.19%)

USD 134.67B
GILD Gilead Sciences Inc

+0.38 (+0.42%)

USD 111.44B
BIIB Biogen Inc

+3.41 (+1.97%)

USD 25.32B
GRFS Grifols SA ADR

+0.49 (+5.57%)

USD 6.92B
AMRN Amarin Corporation PLC

+0.02 (+3.06%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.02 (+1.08%)

USD 0.03B
SCLX Scilex Holding Company

+0.09 (+8.83%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.44% 60% D- 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.44% 60% D- 29% F
Trailing 12 Months  
Capital Gain -50.85% 20% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.85% 20% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -22.74% 30% F 11% F
Dividend Return -22.74% 30% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.32% 20% F 41% F
Risk Adjusted Return -49.08% 30% F 14% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector